Organoprotecive effects of angiotensin II receptor blockers in patients with type 2 diabetes mellitus

Organoprotecive effects of angiotensin II receptor blockers in patients with type 2 diabetes mellitus

High prevalence of arterial hypertension and related cardiovascular complications dictates the necessity of preparations possessed of markedorganoprotective activity and good tolerability. The currently available data suggest advantages of iACE and ARB as preparations for the treatmentof cardiovascu...

Full description

Bibliographic Details
Main Authors:	Ivona Yanovna Yarek-Martynova, Minara Shamkhalovna Shamkhalova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2010-06-01
Series:	Сахарный диабет
Subjects:	telmisartan angiotensin ii ontarget transcend
Online Access:	https://www.dia-endojournals.ru/jour/article/view/5675

Similar Items

Telmisartan and cardioprotection
by: McFarlane S
Published: (2011-11-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

FROM HOPE TRIAL TO ONTARGET TRIAL: THE «HOPE» TO REACH THE «TARGET» - TO IMPROVE PROGNOSIS IN HIGH RISK PATIENTS
by: Yu. M. Lopatin
Published: (2016-01-01)

Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical application
by: Maksimov M.L., et al.
Published: (2017-02-01)

Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical application
by: M L Maksimov, et al.
Published: (2017-03-01)

Angiotensin receptor blockers: rational prescription tailored to the cardiovascular risk and comorbidities
by: V. I. Podzolkov, et al.
Published: (2018-12-01)

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
by: Hiroji Uemura, et al.
Published: (2011-12-01)

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
by: Hiroji Uemura, et al.
Published: (2011-12-01)

Chronic Lithium Toxicity in Old Age Patients Taking Angiotensin Receptor Blocker: A Case Report
by: Asim Pandey, et al.
Published: (2023-11-01)

Left ventricular hypertrophy and renin-angiotensin-aldosterone system: AT1-receptor blockers are in the focus
by: A V Barsukov, et al.
Published: (2013-03-01)

Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats
by: Zheng RH, et al.
Published: (2019-08-01)

What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?
by: Mallat Samir G
Published: (2012-04-01)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
by: Hyun Woo Lee, et al.
Published: (2021-03-01)

Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials
by: Rodolfo Pedro Rothlin, et al.
Published: (2021-03-01)

Effects of two different angiotensin receptor blockers on blood glucose level and HbA1c in type-2 diabetes mellitus patients with hypertension
by: Shafat Iqbal Bhati, et al.
Published: (2023-10-01)

TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY
by: V. I. Podzolkov, et al.
Published: (2015-12-01)

Effect of angiotensin receptor blockers and angiotensin‐converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease
by: Terry Huh, et al.
Published: (2021-01-01)

Advance in Research of Angiotensin II and Its Receptor and Malignant Tumor
by: Lulu SUN, et al.
Published: (2016-09-01)

Angiotensin II receptor blockers as a risk factor for skin ulcers
by: Raúl Gonzalez-Fregoso, et al.
Published: (2021-10-01)

The renin-angiotensin system and its blockers
by: Igić Rajko, et al.
Published: (2014-01-01)

Issledovanie ONTARGET: Telmisartan ne ustupaet po effektivnosti ramiprilu u patsientov s vysokim riskom serdechno-sosudistykh oslozhneniy / sakharnym diabetom
by: Olga Konstantinovna Vikulova, et al.
Published: (2008-06-01)

Central blood pressure lowering effect of telmisartan‐rosuvastatin single‐pill combination in hypertensive patients combined with dyslipidemia: A pilot study
by: JungMin Choi, et al.
Published: (2021-09-01)

Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria
by: Feng-Yi Hsu, et al.
Published: (2017-06-01)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
by: Graham J. Moore, et al.
Published: (2021-07-01)

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
by: John Matsoukas, et al.
Published: (2021-01-01)

Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)

Use of Angiotensin Receptor Blockers in Combination Therapy of Patients with Essential Hypertension and Diabetes Mellitus
by: M.D. Ivanova, et al.
Published: (2015-04-01)

ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASE: WHAT TO CHOOSE?
by: K. A. Ghyamdzhyan, et al.
Published: (2022-12-01)

Angiotensin 1-7 receptor and angiotensin ii receptor 2 blockades prevent the increased serum and kidney nitric oxide levels in response to angiotensin ii administration: Gender-related difference
by: Tahereh Safari, et al.
Published: (2013-01-01)

Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
by: Paweł Bryniarski, et al.
Published: (2022-02-01)

Effect of angiotensin II type 1 receptor blocker and angiotensin converting enzyme inhibitor on the intraocular growth factors and their receptors in streptozotocin-induced diabetic rats
by: Ik Soo Byon, et al.
Published: (2017-06-01)

The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects
by: Hirotetsu Takagi, et al.
Published: (2021-03-01)

An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release
by: Sigal Fleisher-Berkovich, et al.
Published: (2023-11-01)

Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk
by: Farsang C
Published: (2011-09-01)

Place of angiotensin receptor blockers in antihypertensive therapy
by: A I Martynov, et al.
Published: (2014-03-01)

Cardiometabolic properties of telmisartan: new perspectives for use
by: O. M. Drapkina, et al.
Published: (2015-12-01)

Angiotensin-Converting Enzyme Inhibitor / Angiotensin II Receptor Blocker in COVID-19: a Double-edged Sword or a Myth
by: Kunal Bikram Shaha, et al.
Published: (2020-05-01)

Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease
by: Ping-Min Chen, et al.
Published: (2014-04-01)

Potential use of angiotensin receptor blockers in skin pathologies
by: Keshvad Hedayatyanfard, et al.
Published: (2023-07-01)

The effects of central angiotensin II and its specific blockers on nociception: Possible interactions with oxidative stress status
by: Arcan Oana, et al.
Published: (2013-01-01)